Skip to content
Research Article Open access CC BY 4.0

Challenges in the Treatment of Co-infection of Visceral Leishmaniasis and Hepatitis B/C Viruses

Roshan Kamal Topno, Maneesh Kumar, Major Madhukar, Vidya Nand Rabi Das, Rishikesh Kumar, Kanhaiya Agrawal, Niyamat Ali Siddiqui, Subhash Kumar, Krishna Pandey

International Journal of TROPICAL DISEASE & Health · pp. 19–26 · Published 19 Aug 2024

10.9734/ijtdh/2024/v45i81578

Abstract

There is a significant research gap in India due to incomplete investigation of seroprevalence of co-infection with visceral leishmaniasis (VL), hepatitis B (HBV) and hepatitis C (HCV). This study attempts to fill this gap by providing an in-depth analysis of the prevalence and consequences of these co-infections. The study of 32 VL patients revealed that 28 (8.88%) tested positive for HBV, 1 (0.317%) for HCV and 3 (0.95%) for both HBV and HCV. These results highlight how difficult it is to treat people with two diseases at the same time. An example of how co-infection makes treatment much more difficult is the fact that a patient with both VL and HBV required six courses of anti-leishmaniasis medication. The study shows how important it is for VL patients to be tested regularly for HBV and HCV to improve treatment response and support India's plan to get rid of kala-azar. Accurate identification of co-infections is necessary to reduce the overall burden of the disease and develop effective treatment regimens. Systematic testing of VL patients for HBV and HCV not only helps in controlling and perhaps even eliminating kala-azar, but also makes it easier to treat each patient as an individual, improving their health. In areas where viral hepatitis is prevalent, this strategy is particularly important as these diseases represent a double burden on public health. Implementing integrated treatment regimens and routine screening can reduce the impact of co-infection and advance the public health goal of kala-azar elimination. To improve patient outcomes and advance public health goals, the results of this study strongly support the integration of comprehensive screening programs into existing healthcare systems to improve the treatment of VL patients.

Visceral Leishmaniasis (VL) Hepatitis B Virus (HBV) Hepatitis C Virus (HCV) rK-39

References (21)

  1. 1 Regulation of immunity during visceral Leishmania infection [DOI]
  2. 2 Current Scenario of Hepatitis B and Its Treatment in India [DOI]
  3. 3 From Infection to Death: An Overview of the Pathogenesis of Visceral Leishmaniasis [DOI]
  4. 4 Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review [DOI]
  5. 5 Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes [DOI]
  6. 6 Effects of Visceralising Leishmania on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective [DOI]
  7. 7 Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (FungisomeTM) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy [DOI]
  8. 8 Visceral leishmaniasis: An overview of vaccine adjuvants and their applications [DOI]
  9. 9 Visceral Leishmaniasis in West Africa: Clinical Characteristics, Vectors, and Reservoirs [DOI]
  10. 10 Viral Hepatitis as a Public Health Concern: A Narrative Review About the Current Scenario and the Way Forward [DOI]
  11. 11 Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece [DOI]
  12. 12 Immune balance in Hepatitis B Infection: Present and Future Therapies [DOI]
  13. 13 Ensuring access to essential health products: Lessons from Colombia’s leishmaniasis control and elimination initiative [DOI]
  14. 14 Hepatitis B and C Viruses, their coinfection and correlations in chronic liver disease patients: A tertiary care hospital study [DOI]
  15. 15 Visceral Leishmaniasis with Endobronchial Involvement in an Immunocompetent Adult [DOI]
  16. 16 Modeling and Docking of Cysteine Protease-A (CPA) of Leishmania donovani [DOI]
  17. 17 Advanced case of PKDL due to delayed treatment: A rare case report [DOI]
  18. 18 Noninvasive Sweat-Based Diagnosis of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis [DOI]
  19. 19 Direct-acting antivirals and visceral leishmaniasis: a case report [DOI]
  20. 20 Post Kala-Azar Dermal Leishmaniasis Following Treatment with 10 mg/kg of Single Dose AmBisome for Visceral Leishmaniasis in Bihar, India [DOI]
  21. 21 Climate Change and Health Impacts on Vulnerable Communities: The Case of Kala-Azar (Visceral Leishmaniasis) in Nepal [DOI]

Cited by 6

Implementing microbiome analysis in clinical practice: overcoming challenges

Maneesh Kumar, Suman Kumar, Ratnesh Kumar · Elsevier eBooks · 2026

Systemic Lupus Erythematosus Pathogenesis and Management

Maneesh Kumar, Suman Kumar, Pratima Gupta · Springer eBooks · 2026

Molecular Mechanisms of Viral Genome Replication During Infection

Suman Kumar, Bibekananda Bhoi, Neha Sharad · IntechOpen eBooks · 2026

Showing 3 of 6 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

34

Page views

0

PDF downloads

2

Outbound clicks

6

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.